Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | FGFR3 | P22607 | 19/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 18/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 18/20 | 0.49 |
| ▸ | KDR | P35968 | 17/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.48 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12178898 | 0.82 | TLR9 (0.55) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL16642057 | 0.82 | MAPK1 (0.52) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL2592957 | 0.82 | MAPK1 (0.52) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL29590784 | 0.79 | MAPK1 (0.59) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL5211835 | 0.79 | MAPK1 (0.59) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL22075052 | 0.77 | MAPK1 (0.41) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL29400331 | 0.76 | TLR9 (0.63) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL29590529 | 0.76 | MAPK1 (0.52) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL30646549 | 0.76 | MAPK1 (0.52) | MAPK1FGFR3FGFR1FGFR2KDR | |
| SCHEMBL27090893 | 0.76 | MAPK1 (0.52) | MAPK1FGFR3FGFR1FGFR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2020-04-30 | — | — | US | disclosed |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2018-05-10 | — | — | US | disclosed |
| US-9850228-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131153-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | MAPK1 290/4885FGFR3 2685/4885FGFR1 1681/4885 |
| US-20180127397-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | MAPK1 290/4885FGFR3 2685/4885FGFR1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.